Jun 20, 2016 9:30am EDT Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
Jun 05, 2016 9:05am EDT Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting
May 03, 2016 9:00am EDT Adaptimmune to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
Apr 27, 2016 1:46pm EDT Adaptimmune to Present at the Deutsche Bank Securities 41st Annual Health Care Conference
